Organon OGN Brenzys — Revenue

Other product segments

Similar metrics at other companies

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

AEPCommercial Revenues — Revenue

$1.21B+15.4%

EQIXRecurring revenues — Revenue

$2.38B+10.9%

GCTProduct revenues — Revenue

$290.82M+28.9%

FAQ

What is Organon's brenzys — revenue?

Organon (OGN) reported brenzys — revenue of $20M in Q1 2026.

How has Organon's brenzys — revenue changed year-over-year?

Organon's brenzys — revenue increased by 42.9% year-over-year, from $14M to $20M.

What is the long-term trend for Organon's brenzys — revenue?

Over 4 years (2021 to 2025), Organon's brenzys — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $63M to $80M.

What does brenzys — revenue mean?

This metric represents the total gross sales generated by the Brenzys product line, a biosimilar therapy within the company's portfolio. It serves as a key indicator of market adoption and competitive performance for this specific therapeutic asset. Tracking these revenues helps investors assess the growth trajectory and commercial viability of the biosimilars segment.